Recent publications · Crossref
5 total works indexed
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
· 2013 · cited 2,888x
- Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
· 2021 · cited 1,552x
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
· 2014 · cited 1,510x
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients
· 2010 · cited 1,157x
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
· 2016 · cited 947x
via Crossref · CC0
Available in 10 languages
via Wikidata sitelinks · CC0